Compounds > methyl 4,5-didehydrojasmonate

Page last updated: 2024-11-13

methyl 4,5-didehydrojasmonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methyl 4,5-didehydrojasmonate: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	44562749
CHEMBL ID	443868
SCHEMBL ID	11419180
MeSH ID	M0509314

Synonyms (6)

Synonym
methyl 4,5-didehydrojasmonate
CHEMBL443868
4-methoxycarbonylmethyl-5-(cis-2-pentenyl)-2-cyclopentenone
RRZQRPDFHNQSJD-PLNGDYQASA-N
SCHEMBL11419180
methyl 4-oxo-5-(2z)-2-penten-1-yl-2-cyclopentene-1-acetate

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay ID	Title	Year	Journal	Article
AID411871	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of TNFalpha production at 12.5 uM after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID411690	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells at 50 uM after 24 hrs by MTT assay	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID670250	Cytotoxicity in mouse RAW264.7 cells after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	In vitro stability and in vivo anti-inflammatory efficacy of synthetic jasmonates.
AID411869	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production at 12.5 uM after 24 hrs by Griess reagent method	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID411689	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells at 100 uM after 24 hrs by MTT assay	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID670248	Stability in presence of porcine liver esterase assessed as esterase-mediated compound hydrolysis by measuring ratio of intact compounds and their corresponding acids in pH 7.4 phosphate buffer at 37 degC at 60 mins post incubation by RP-HPLC	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	In vitro stability and in vivo anti-inflammatory efficacy of synthetic jasmonates.
AID411686	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production at 50 uM after 24 hrs by Griess reagent method	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID411688	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of TNFalpha production at 50 uM after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID670247	Stability in presence of porcine liver esterase assessed as esterase-mediated compound hydrolysis by measuring ratio of intact compounds and their corresponding acids in pH 7.4 phosphate buffer at 37 degC at 30 mins post incubation by RP-HPLC	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	In vitro stability and in vivo anti-inflammatory efficacy of synthetic jasmonates.
AID411866	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of IL6 production at after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID670249	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of nitric oxide production incubated for 24 hrs by ELISA	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	In vitro stability and in vivo anti-inflammatory efficacy of synthetic jasmonates.
AID411868	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production at 25 uM after 24 hrs by Griess reagent method	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID411867	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of TNFalpha production after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID411865	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID411685	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production at 100 uM after 24 hrs by Griess reagent method	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID411687	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of IL6 production at 50 uM after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
AID670251	Selectivity index, ratio of TC50 for mouse RAW264.7 cells to EC50 for antiinflammatory activity in LPS-activated mouse RAW264.7 cells	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	In vitro stability and in vivo anti-inflammatory efficacy of synthetic jasmonates.
AID411870	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of IL6 production at 12.5 uM after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24	New jasmonate analogues as potential anti-inflammatory agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.63 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.42 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.07	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.74	3	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
isopentenyladenosine Isopentenyladenosine: N(6)-[delta(3)-isopentenyl]adenosine. Isopentenyl derivative of adenosine which is a member of the cytokinin family of plant growth regulators.. N(6)-(Delta(2)-isopentenyl)adenosine : A nucleoside analogue in which adenosine has been modified by substitution at the 6-amino nitrogen by a Delta(2)-isopentenyl group.	2.05	1	0	N-ribosyl-N(6)-isopentenyladenine; nucleoside analogue	antineoplastic agent; plant growth regulator; plant metabolite
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.05	1	0	benzenes; phenyl acetates
n(6)-(delta(2)-isopentenyl)adenine N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group.	2.05	1	0	6-isopentenylaminopurine	cytokinin
MeJA [no description available]	2.04	1	0	Jasmonate derivatives
methyl jasmonate [no description available]	2.05	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Hematologic Malignancies [description not available]	0	2.05	1	0
Leucocythaemia [description not available]	0	2.05	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	2.05	1	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	0	2.05	1	0